U.S. License Holder:
Schering
Date of License:
January-19-2001
Last Update:
Dec-15-2024
FDA-Approved Indications
PEGINTRON (peginterferon alfa-2b) is an antiviral indicated for treatment of Chronic Hepatitis C (CHC) in patients with compensated liver disease.
SYLATRON (peginterferon alfa-2b) is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy.